Meeting
2013 Breast Cancer Symposium
Can Oncotype DX recurrence score (RS) be used in Luminal A and Luminal B breast cancer patients (pts) to predict the likely benefit of chemotherapy? A retrospective unicentric study in Spanish population.
Authors
Laura G. Estevez
Centro Integral Oncológico Clara Campal, Madrid, Spain
Laura G. Estevez , Isabel Calvo , Maria Fernandez-Abad , Juan Jose Cruz , Ana Suarez , Fernando Lopez-Rios , Manuel Hidalgo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session A
Track
Local/Regional Therapy,Risk Assessment, Prevention, Detection, and Screening
Sub Track
High Risk
Citation
J Clin Oncol 31, 2013 (suppl 26; abstr 40)
DOI
10.1200/jco.2013.31.26_suppl.40
Abstract #
40
Poster Bd #
C22
Abstract Disclosures
Similar Posters
Poster
2012 Breast Cancer Symposium
Molecular subtyping using MammaPrint and BluePrint as an outcome predictor in U.S. breast cancer (BC) patients.
First Author: Katharine Yao
Poster
2012 ASCO Annual Meeting
Molecular subtyping using MammaPrint and BluePrint as an outcome predictor in 180 U.S. breast cancer (BC) patients.
First Author: Lisette Stork-Sloots
Poster
2022 ASCO Annual Meeting
Estimating survival benefit of adjuvant chemotherapy in postmenopausal women with pT1-2N0 early-stage breast cancer and Oncotype DX recurrence score > 26: A National Cancer Database (NCDB) analysis.
First Author: Lifen Cao
